USE OF SPHINGOLIPIDS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND METABOLIC SYNDROME

摘要

The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment of insulin resistance, diabetes mellitus type 2 and/or metabolic syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I):; ;whereinZ is R₃ or —CH(OH)—R₃;A is sulphate, sulphonate, phosphate, phosphonate or —C(O)O—;R₁ is H, hydroxyl, alditol, aldose, an alcohol, C₁-C₆ alkyl or amino acid;R₂ is H or unsaturated or saturated (C₁-C₃₀) alkyl chain;R₃ is unsaturated or saturated (C₁-C₃₀) alkyl chain;Q₁ is a primary amine group (—NH₂), secondary amine group (—NH—) or an amide group (—NH—CO—); andt is 0 or 1, or a precursor, a derivative or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and/or treatment of a disorder selected from the group consisting of insulin resistance, diabetes type 2 and metabolic syndrome.